Novo Nordisk A/S has recently acquired Catalent, a leading pharmaceutical company. This strategic move is expected to enhance Novo Nordisk’s capabilities and offerings in the pharmaceutical industry. The acquisition of Catalent by Novo Nordisk is a significant development that will further strengthen Novo Nordisk’s position in the market. This acquisition reflects Novo Nordisk’s commitment to growth and innovation in the pharmaceutical sector. With this new partnership, Novo Nordisk is poised to expand its reach and deliver even more value to its customers.